Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
Key Laboratory of Cardiovascular Diseases at The Second Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, China.
FEBS J. 2020 Dec;287(24):5260-5283. doi: 10.1111/febs.15357. Epub 2020 May 22.
Neointimal hyperplasia (NIH) is a pathological process occurring in the blood vessel wall during atherosclerosis and in-stent restenosis (ISR). Due to the abundance of vascular smooth muscle cells (VSMCs) within neointimal lesions, VSMCs have long been considered as a key cellular target in preventing NIH. Noncoding RNA molecules such as microRNA (miRNAs), long noncoding RNA (lncRNAs) and circular RNAs (circRNAs) expressed in VSMCs offer unique therapeutic targets for tackling VSMC phenotype switching, proliferation, migration and apoptosis processes responsible for promoting NIH. In this review, we provide an extensive overview of VSMC RNA biology, highlighting the most recent discoveries in the field of lncRNAs and circRNAs, with the aim of identifying key molecular players that could be harnessed for future therapeutic interventions, in our quest to halt NIH in vascular disease.
血管平滑肌细胞 RNA 生物学：治疗血管疾病中新生内膜增生的潜在靶点
血管平滑肌细胞（VSMCs）中的非编码 RNA 分子，如 miRNA、lncRNA 和 circRNA，为治疗 VSMC 表型转化、增殖、迁移和凋亡过程提供了独特的治疗靶点，这些过程是促进 NIH 的关键因素。在这篇综述中，我们广泛概述了 VSMC 的 RNA 生物学，强调了 lncRNA 和 circRNA 领域的最新发现，旨在确定关键的分子靶点，为未来的治疗干预提供依据，以阻止血管疾病中的 NIH。
